The global demand for Autism treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Autism pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Autism pipeline companies from advancing their products into Phase 3 or Phase 4.
Autism Report Description
The 2019 pipeline study on Autism pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Autism pipeline compounds.
The Autism pipeline guide presents information on all active drugs currently being developed for Autism. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Autism pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Autism drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Autism product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Autism pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Autism pipeline report includes
For each pipeline candidate, the following details are provided:
Reasons to Buy
The report will be delivered in 2 working days.
Autism Report Description
The 2019 pipeline study on Autism pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Autism pipeline compounds.
The Autism pipeline guide presents information on all active drugs currently being developed for Autism. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Autism pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Autism drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Autism product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Autism pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Autism pipeline report includes
- An overview of Autism disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of Autism pipeline
- Company wise list of Autism pipeline
- Mechanism of Action wise Autism pipeline
For each pipeline candidate, the following details are provided:
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials/Results
- Company Overview and Recent Developments
Reasons to Buy
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Autism pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Autism pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into companies participating in Autism pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Table of Contents
1.1 List of Tables1.2 List of Figures42. Latest Autism Drug Pipeline Developments, 2019
2. Global Autism Pipeline Overview
3. Executive Summary
4 4D Pharma PLC Autism Pipeline Details
5 AgeneBio Inc Autism Pipeline Details
6 APeT Holding BV Autism Pipeline Details
7 Axial Biotherapeutics Autism Pipeline Details
8 Axim Biotech In Autism Pipeline Details
9 Bantam Pharmaceutical LLC Autism Pipeline Details
10 BioHealthonomics Inc Autism Pipeline Details
11 BrainStorm Cell Therapeutics Inc Autism Pipeline Details
12 cannabis science Inc Autism Pipeline Details
13 Cennerv Pharma (S) Pte Ltd Autism Pipeline Details
14 Coronis NeuroSciences Ltd Autism Pipeline Details
15 Curemark LLC Autism Pipeline Details
16 Cytocom Inc Autism Pipeline Details
17 Evgen Pharma Plc Autism Pipeline Details
18 F. Hoffmann-La Roche Ltd Autism Pipeline Details
19 GW Pharmaceuticals Plc Autism Pipeline Details
20 Heptares Therapeutics Ltd Autism Pipeline Details
21 Immuron Ltd Autism Pipeline Details
22 Intra-Cellular Therapies Inc Autism Pipeline Details
23 MedDay SA Autism Pipeline Details
24 Neurochlore Autism Pipeline Details
25 Omeros Corporation Autism Pipeline Details
26 OptiNose US Inc Autism Pipeline Details
27 Ovensa Inc Autism Pipeline Details
28 Panorama Research Inc Autism Pipeline Details
29 Park Active Molecules Autism Pipeline Details
30 RespireRx Pharmaceuticals Inc Autism Pipeline Details
31 Reviva Pharmaceuticals Inc Autism Pipeline Details
32 RogCon U.R. Inc Autism Pipeline Details
33 Rugen Therapeutics R&D (Shanghai) Co Ltd Autism Pipeline Details
34 Second Genome Inc Autism Pipeline Details
35 Seropeutics LLC Autism Pipeline Details
36 Stem Cell Medicine Ltd Autism Pipeline Details
37 Sumitomo Chemical Co Ltd Autism Pipeline Details
38 System1 Biosciences Inc Autism Pipeline Details
39 Translational Biosciences Autism Pipeline Details
40 Yamo Pharmaceuticals LLC Autism Pipeline Details
41 Zelda Therapeutics Pty Ltd Autism Pipeline Details
43. Appendix
Companies Mentioned
- 4D Pharma PLC
- AgeneBio Inc
- APeT Holding BV
- Axial Biotherapeutics
- Axim Biotech In
- Bantam Pharmaceutical LLC
- BioHealthonomics Inc
- BrainStorm Cell Therapeutics Inc
- cannabis science Inc
- Cennerv Pharma (S) Pte Ltd
- Coronis NeuroSciences Ltd
- Curemark LLC
- Cytocom Inc
- Evgen Pharma Plc
- F. Hoffmann-La Roche Ltd
- GW Pharmaceuticals Plc
- Heptares Therapeutics Ltd
- Immuron Ltd
- Intra-Cellular Therapies Inc
- MedDay SA
- Neurochlore
- Omeros Corporation
- OptiNose US Inc
- Ovensa Inc
- Panorama Research Inc
- Park Active Molecules
- RespireRx Pharmaceuticals Inc
- Reviva Pharmaceuticals Inc
- RogCon U.R. Inc
- Rugen Therapeutics R&D (Shanghai) Co Ltd
- Second Genome Inc
- Seropeutics LLC
- Stem Cell Medicine Ltd
- Sumitomo Chemical Co Ltd
- System1 Biosciences Inc
- Translational Biosciences
- Yamo Pharmaceuticals LLC
- Zelda Therapeutics Pty Ltd